drugset / Trial / NCT04853329
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available.
Timeline
- Start
- 2021-12-13
- Primary completion
- 2023-01-31
- Completion
- 2023-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JMT601 | Unknown | 1 mg/kg | Intravenous |
| Subject | JMT601 | Unknown | 3 mg/kg | Intravenous |
| Subject | JMT601 | Unknown | 6 mg/kg | Intravenous |
| Subject | JMT601 | Unknown | 12 mg/kg | Intravenous |
| Subject | JMT601 | Unknown | 20 mg/kg | Intravenous |